成都(dou)圣諾(nuo)(nuo)生(sheng)(sheng)物(wu)(wu)(wu)科(ke)技股份有限公司(si)(以下(xia)簡稱(cheng)“圣諾(nuo)(nuo)生(sheng)(sheng)物(wu)(wu)(wu)”或(huo)“公司(si)”)是一家擁有多(duo)(duo)(duo)肽(tai)(tai)合成和修飾核心(xin)技術(shu)的高新(xin)技術(shu)企(qi)業,具有先進(jin)、高效的多(duo)(duo)(duo)肽(tai)(tai)藥(yao)(yao)(yao)物(wu)(wu)(wu)工(gong)藝(yi)研(yan)發和規模化生(sheng)(sheng)產(chan)(chan)(chan)能力(li)。公司(si)主營業務(wu)為(wei)自主研(yan)發、生(sheng)(sheng)產(chan)(chan)(chan)和銷售(shou)在國內(nei)外具有較(jiao)大市場容(rong)量及(ji)(ji)(ji)較(jiao)強競爭力(li)的多(duo)(duo)(duo)肽(tai)(tai)原料藥(yao)(yao)(yao)和制劑產(chan)(chan)(chan)品,同時(shi)公司(si)依托在多(duo)(duo)(duo)肽(tai)(tai)藥(yao)(yao)(yao)物(wu)(wu)(wu)研(yan)發和規模化生(sheng)(sheng)產(chan)(chan)(chan)領域的技術(shu)優勢,為(wei)國內(nei)外醫藥(yao)(yao)(yao)企(qi)業提(ti)供多(duo)(duo)(duo)肽(tai)(tai)創(chuang)新(xin)藥(yao)(yao)(yao)藥(yao)(yao)(yao)學研(yan)究(jiu)服(fu)務(wu)、多(duo)(duo)(duo)肽(tai)(tai)類產(chan)(chan)(chan)品定制生(sheng)(sheng)產(chan)(chan)(chan)服(fu)務(wu)以及(ji)(ji)(ji)多(duo)(duo)(duo)肽(tai)(tai)藥(yao)(yao)(yao)物(wu)(wu)(wu)生(sheng)(sheng)產(chan)(chan)(chan)技術(shu)轉讓(rang)服(fu)務(wu)。此外,公司(si)還提(ti)供小分子化學藥(yao)(yao)(yao)物(wu)(wu)(wu)左西孟旦制劑代加(jia)工(gong)及(ji)(ji)(ji)左西孟旦原料藥(yao)(yao)(yao)生(sheng)(sheng)產(chan)(chan)(chan)、出口銷售(shou)業務(wu)。
圣(sheng)諾生(sheng)物(wu)(wu)具備多(duo)(duo)(duo)肽(tai)原料藥(yao)(yao)(yao)(yao)(yao)和(he)制(zhi)劑(ji)的(de)(de)全(quan)流程研(yan)(yan)(yan)發(fa)(fa)管線(xian)和(he)全(quan)產(chan)業(ye)鏈平臺,能夠為多(duo)(duo)(duo)肽(tai)創(chuang)新(xin)(xin)(xin)藥(yao)(yao)(yao)(yao)(yao)和(he)仿制(zhi)藥(yao)(yao)(yao)(yao)(yao)提(ti)供從工(gong)藝(yi)路(lu)線(xian)設計(ji),到(dao)小試(shi)、中試(shi)、工(gong)藝(yi)驗證和(he)質量研(yan)(yan)(yan)究等藥(yao)(yao)(yao)(yao)(yao)學(xue)(xue)研(yan)(yan)(yan)究服(fu)務,以及藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)研(yan)(yan)(yan)發(fa)(fa)及商(shang)(shang)業(ye)化(hua)生(sheng)產(chan)所需原料藥(yao)(yao)(yao)(yao)(yao)、制(zhi)劑(ji)產(chan)品的(de)(de)全(quan)鏈條定(ding)制(zhi)生(sheng)產(chan)服(fu)務,涵蓋從藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)發(fa)(fa)現、臨(lin)床前研(yan)(yan)(yan)究,到(dao)臨(lin)床試(shi)驗和(he)上市(shi)(shi)銷售的(de)(de)完整藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)開發(fa)(fa)周期。公(gong)司(si)憑借多(duo)(duo)(duo)肽(tai)合成和(he)修飾(shi)核心技術(shu)優勢,在多(duo)(duo)(duo)肽(tai)藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)研(yan)(yan)(yan)發(fa)(fa)生(sheng)產(chan)領域獲(huo)得(de)較高的(de)(de)知名(ming)度和(he)認(ren)可度,先后為蘇州派格生(sheng)物(wu)(wu)、百奧泰(tai)生(sheng)物(wu)(wu)、八加(jia)一等新(xin)(xin)(xin)藥(yao)(yao)(yao)(yao)(yao)研(yan)(yan)(yan)發(fa)(fa)企業(ye)和(he)科研(yan)(yan)(yan)機構提(ti)供了30余(yu)個(ge)(ge)項目(mu)的(de)(de)藥(yao)(yao)(yao)(yao)(yao)學(xue)(xue)研(yan)(yan)(yan)究及定(ding)制(zhi)生(sheng)產(chan)服(fu)務,其中1個(ge)(ge)多(duo)(duo)(duo)肽(tai)創(chuang)新(xin)(xin)(xin)藥(yao)(yao)(yao)(yao)(yao)已獲(huo)批上市(shi)(shi)進入商(shang)(shang)業(ye)化(hua)階(jie)段,1個(ge)(ge)多(duo)(duo)(duo)肽(tai)創(chuang)新(xin)(xin)(xin)藥(yao)(yao)(yao)(yao)(yao)已申報生(sheng)產(chan),另有10個(ge)(ge)多(duo)(duo)(duo)肽(tai)創(chuang)新(xin)(xin)(xin)藥(yao)(yao)(yao)(yao)(yao)進入臨(lin)床試(shi)驗階(jie)段。
公司挑選在國(guo)內(nei)(nei)外具有(you)較大(da)市(shi)場容量及(ji)較強市(shi)場競爭力的多肽仿制(zhi)藥(yao)品(pin)種(zhong)(zhong)進行研(yan)發(fa)(fa),已掌握15個(ge)品(pin)種(zhong)(zhong)原(yuan)料藥(yao)的規模化(hua)生(sheng)產(chan)(chan)(chan)技術,其中9個(ge)品(pin)種(zhong)(zhong)在國(guo)內(nei)(nei)取(qu)得(de)生(sheng)產(chan)(chan)(chan)批件、9個(ge)品(pin)種(zhong)(zhong)獲(huo)得(de)美(mei)國(guo)DMF備案(an)(其中8個(ge)品(pin)種(zhong)(zhong)處于激活狀態),延伸開發(fa)(fa)的8個(ge)多肽制(zhi)劑品(pin)種(zhong)(zhong)在國(guo)內(nei)(nei)取(qu)得(de)了12個(ge)生(sheng)產(chan)(chan)(chan)批件,產(chan)(chan)(chan)品(pin)涵蓋免(mian)疫、消化(hua)道、抗病(bing)毒、婦產(chan)(chan)(chan)科、糖尿(niao)病(bing)、心腦血管(guan)、罕見病(bing)、骨科等(deng)等(deng)多肽藥(yao)物(wu)發(fa)(fa)揮(hui)重要作用的領(ling)域。公司多肽制(zhi)劑產(chan)(chan)(chan)品(pin)注射(she)用恩夫(fu)韋(wei)肽和卡貝縮(suo)宮素注射(she)液為(wei)國(guo)內(nei)(nei)首仿多肽藥(yao)物(wu);比伐蘆定、利拉(la)魯肽、胸腺法新、艾替(ti)班(ban)特、恩夫(fu)韋(wei)肽等(deng)合成難度較大(da)的仿制(zhi)原(yuan)料藥(yao)已出口至歐美(mei)、印(yin)度、韓國(guo)等(deng)國(guo)際市(shi)場。